Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

NANOMEDICINE

Protected rituximab aims at brain metastases

Nature Biomedical Engineering volume 3, pages 678–679 (2019)Cite this article

Subjects

Encapsulation of the therapeutic monoclonal antibody rituximab, and its molecular targeting to brain metastases of B-cell lymphoma, significantly boosts the antibody’s therapeutic effectiveness in mice.

Metastatic disease in the nervous system is resistant to most first-line therapies1,2. The failure of treatments against metastases in the central nervous system (CNS; ref. 3), which develop in 15–40% of all cancers, is generally due to limited drug permeability across physiological barriers, in particular the blood–brain barrier (BBB). The BBB, which is primarily formed by endothelial cells with tight junctions, is a continuous cellular wall that tightly regulates the traffic of immune cells, xenobiotics (including small and large therapeutic compounds) and endogenous molecules into the brain parenchyma4.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Encapsulation and functionalization of a therapeutic antibody against lymphomas.

References

  1. Wong, H. L., Wu, X. Y. & Bendayan, R. Adv. Drug Deliv. Rev. 64, 686–700 (2012).

    Article  CAS  Google Scholar 

  2. Banks, W. A. Nat. Rev. Drug Discov. 15, 275–292 (2016).

    Article  CAS  Google Scholar 

  3. Aragon-Ching, J. B., Williams, K. M. & Gulley, J. L. Front. Biosci. 12, 4957–4971 (2007).

    Article  CAS  Google Scholar 

  4. Bendayan, R., Lee, G. & Bendayan, M. Microsc. Res. Tech. 57, 365–380 (2002).

    Article  CAS  Google Scholar 

  5. Rubenstein, J. L. et al. Blood 101, 466–468 (2003).

    Article  CAS  Google Scholar 

  6. Gan, H. K., Azad, A., Cher, L. & Mitchell, P. L. Neuro. Oncol. 12, 212–215 (2010).

    Article  Google Scholar 

  7. Rezvani, A. R. & Maloney, D. G. Best. Pract. Res. Clin. Haematol. 24, 203–216 (2011).

    Article  CAS  Google Scholar 

  8. Abès, R., Gélizé, E., Fridman, W. H. & Teillaud, J. L. Blood 116, 926–934 (2010).

    Article  Google Scholar 

  9. Rubenstein, J. L., Gupta, N. K., Mannis, G. N., Lamarre, A. K. & Treseler, P. Blood 122, 2318–2330 (2013).

    Article  CAS  Google Scholar 

  10. Wen, J. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-019-0434-z (2019).

    Article  CAS  Google Scholar 

  11. Hussain, S. K. et al. Cancer Epidemiol. Biomark. Prev. 22, 295–307 (2013).

    Article  CAS  Google Scholar 

  12. Melkus, M. W. et al. Nat. Med. 12, 1316–1322 (2006).

    Article  CAS  Google Scholar 

  13. Shi, N., Zhang, Y., Zhu, C., Boado, R. J. & Pardridge, W. M. Proc. Natl Acad. Sci. USA 98, 12754–12759 (2001).

  14. He, C. et al. Adv. Funct. Mater. 28, 1705668 (2018).

    Article  Google Scholar 

  15. Wu, D. et al. Adv. Mater. 31, e1807557 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada

    Reina Bendayan

Authors
  1. Reina Bendayan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Reina Bendayan.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bendayan, R. Protected rituximab aims at brain metastases. Nat Biomed Eng 3, 678–679 (2019). https://doi.org/10.1038/s41551-019-0451-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41551-019-0451-y

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer